Biosimilar deals forge a trio of partnerships

Aflurry of activity in the biosimilar licensing arena has resulted in three new partnerships being struck. Lupin and Mylan have entered a deal for Mylan to sell the Indian firm’s etanercept candidate in various worldwide territories; Prestige Biopharma and Alvogen have agreed a licensing and supply arrangement on Prestige’s trastuzumab in central and eastern Europe (CEE); and Shanghai Henlius Biotech will allow Accord to sell its trastuzumab in more than 70 countries around the globe.

Mylan will have rights to sell Lupin’s proposed etanercept – which completed Phase III trials in February (Generics bulletin, 16 February 2018, page 15) and has so far been filed with the European Medicines Agency (EMA) – in Europe, Australia, New Zealand, Latin America, Africa and “most markets throughout Asia”. In return, Lupin will receive an upfront payment of US$15 million along with commercial milestones and an equal share of net profits